According to CalMatters Housing, California lawmakers have been working on Senate Bill 1094, which would let health insurance companies and pharmacists switch patients from expensive brand-name biologic drugs to cheaper alternatives called biosimilars without requiring a doctor's approval first. The bill does include some protections though, requiring insurance plans to give doctors and patients sixty days' notice before making any switches, and it allows doctors to object if they think the change isn't medically appropriate for their patient.
Senator Akilah Weber Pierson, a San Diego Democrat and obstetrician, introduced this legislation as a way to tackle rising drug costs across California. The reporting shows that prescription drug spending has jumped significantly in recent years, and biologic drugs are a major driver of these increases. According to state data, six of the ten most expensive drugs in California are biologics, which are complex medications grown from living cells rather than manufactured from chemicals.
The potential savings from this bill could be substantial at a system level. A legislative analysis estimates that the measure could reduce overall health insurance spending by roughly ninety million dollars annually, which could translate to individual savings somewhere between ninety-two and three hundred ten dollars per year for the average Californian, depending on their insurance plan. Biosimilars typically cost significantly less than their brand-name versions while maintaining safety and effectiveness according to federal regulators.
There's real concern from medical professionals about unintended consequences. Rheumatologists and some patient advocacy groups worry that switching patients away from medications that are working well simply for financial reasons could disrupt their treatment, especially since many patients with autoimmune diseases have struggled to find the right medication after trying multiple options. A past president of the California Rheumatology Alliance noted that while many patients do fine on biosimilars, some people spent years finding a medication that actually works for their condition.
CalMatters also reports that research hasn't consistently shown that increased biosimilar use actually lowers what patients pay out of pocket, even when insurance companies realize savings. Senator Weber Pierson acknowledged this complexity, noting that the real benefit may come through slower premium increases over time rather than direct refunds to patients. To ensure companies don't simply keep the savings, the bill would require health insurance plans to report annually on where money saved from these switches actually goes.
What I'm seeing locally in the Bay Area and East Bay is that our clients are constantly grappling with rising healthcare costs, and this kind of legislation reflects a real tension in our market. While controlling costs is genuinely important for families and businesses, people also worry about having their medical decisions driven by price rather than what their doctors recommend. It's one more factor adding to the overall cost of living pressures that affect both buyers and sellers in our region.
